Key data on trials exploring the combination of novel agents with lenalidomide and/or anti CD20 monoclonal antibodies
| . | AUGMENT7 (R2 vs rituximab) . | Glofitamab + obinutuzumab9 . | Mosunetuzumab + lenalidomide8 . | EPCORE-NHL2 (epcoritamab + R2)1 . | INMIND (tafa R2 vs R2)10 . |
|---|---|---|---|---|---|
| Study phase | 3 | 1/2 | 1b | 1b/2 | 3 |
| Number of patients | 358 | 19 | 27 | 108 | 548 |
| Median follow-up, mo | 28.3 | 0-5 | NA | 28.2 | 14.1 |
| Patient population Median age (range) FLIPI 3-5 Median prior lines (range) POD24 Refractory to last line Double refractory | 63 (26-88) 34% 1 (1-12) 33% 16% NA | 61 (41-78) 58% 2 (1-5), 53% 42% 37% | 59 (31-79) NR 1 (1-4), 11% NA NA | 65 (30-80) 57% 1 (1-7), 50% 36% 36% | 64 (31-88) 52% 1 (1-10) 32% NA NA |
| ORR | 78% vs 53% | 100% | 92% | 96% | 83.5% vs 72.4% |
| CR | 34% vs 18% | 73.7% | 77% | 88% | 49% vs 39.8% |
| PFS | |||||
| 2-year PFS | 58% vs 36% | NA | NA | 76% | NA |
| Median PFS (mo) | 39 vs 14 (HR, 0.46; P < .001) | NA | NA | Not reached | 22 vs 14 (HR, 0.46; P < .001) |
| Key grade ≥3 adverse events | Neutropenia, 50% vs 13% | NA | Neutropenia, 19% | Neutropenia, 54% COVID-19, 24% Pneumonia, 12% | Neutropenia 39.8% vs 37.5% Pneumonia 8.4% vs 5.1% |
| Discontinuation to adverse events | 9% | NA | 0 | 24% | 11% vs 7% |
| . | AUGMENT7 (R2 vs rituximab) . | Glofitamab + obinutuzumab9 . | Mosunetuzumab + lenalidomide8 . | EPCORE-NHL2 (epcoritamab + R2)1 . | INMIND (tafa R2 vs R2)10 . |
|---|---|---|---|---|---|
| Study phase | 3 | 1/2 | 1b | 1b/2 | 3 |
| Number of patients | 358 | 19 | 27 | 108 | 548 |
| Median follow-up, mo | 28.3 | 0-5 | NA | 28.2 | 14.1 |
| Patient population Median age (range) FLIPI 3-5 Median prior lines (range) POD24 Refractory to last line Double refractory | 63 (26-88) 34% 1 (1-12) 33% 16% NA | 61 (41-78) 58% 2 (1-5), 53% 42% 37% | 59 (31-79) NR 1 (1-4), 11% NA NA | 65 (30-80) 57% 1 (1-7), 50% 36% 36% | 64 (31-88) 52% 1 (1-10) 32% NA NA |
| ORR | 78% vs 53% | 100% | 92% | 96% | 83.5% vs 72.4% |
| CR | 34% vs 18% | 73.7% | 77% | 88% | 49% vs 39.8% |
| PFS | |||||
| 2-year PFS | 58% vs 36% | NA | NA | 76% | NA |
| Median PFS (mo) | 39 vs 14 (HR, 0.46; P < .001) | NA | NA | Not reached | 22 vs 14 (HR, 0.46; P < .001) |
| Key grade ≥3 adverse events | Neutropenia, 50% vs 13% | NA | Neutropenia, 19% | Neutropenia, 54% COVID-19, 24% Pneumonia, 12% | Neutropenia 39.8% vs 37.5% Pneumonia 8.4% vs 5.1% |
| Discontinuation to adverse events | 9% | NA | 0 | 24% | 11% vs 7% |
Patients characteristics are reported for the overall study population (both arms). HR hazard ratio; NA, not available; POD24 progression of disease within 24 months; tafa, tafasitamab.